Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis

被引：0
|
作者：
Pardanani, A. D.
Caramazza, D.
George, G.
Lasho, T. L.
Hogan, W. J.
Litzow, M. R.
Begna, K.
Hanson, C. A.
McClure, R. F.
Bavisotto, L. M.
Smith, G.
Kowalski, M.
Sirhan, S.
Roberts, A. W.
Gupta, V.
Gotlib, J.
Tefferi, A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Porta Clin PLLC, Seattle, WA USA
[3] YM BioSci, Mississauga, ON, Canada
[4] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[5] Royal Melbourne Hopsital, Parkville, Vic, Australia
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6514
引用
收藏
页数：1
相关论文
共 50 条
  • [31] CYT387, a JAK-Specific Inhibitor Impedes Osteoclast Activity and Oophorectomy-Induced Osteoporosis via Modulating RANKL and ROS Signaling Pathways
    Li, Jing
    Liang, Jiamin
    Wu, Liwei
    Xu, Yang
    Xiao, Chengxiang
    Yang, Xue
    Sun, Ran
    Zhao, Jinmin
    Xu, Jiake
    Liu, Qian
    Zhou, Bo
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] JAK2 inhibitor treatment of anemia in myelofibrosis
    Tefferi, Ayalew
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : 995 - 997
  • [33] Significant Improvement in Quality of Life (QoL) in Patients With Chronic Myeloproliferative Neoplasms (CMPN) and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib
    Vargas-Viveros, Pablo
    Hurtado-Monroy, Rafael
    Candelaria-Hernandez, Myrna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S155 - S156
  • [34] MOMELOTINIB HYDROCHLORIDE JAK1/JAK2 inhibitor Treatment of myelofibrosis Treatment of pancreatic cancer
    Price, S.
    George, T.
    Pinilla-Ibarz, J.
    DRUGS OF THE FUTURE, 2015, 40 (09) : 561 - 568
  • [35] Balancing efficacy and safety of JAK inhibitors in myelofibrosis
    Passamonti, Francesco
    LEUKEMIA RESEARCH, 2014, 38 (03) : 290 - 291
  • [36] JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation
    Lu, Z.
    Hong, C. C.
    Jark, P. C.
    Assumpcao, A. L. F. V.
    Bollig, N.
    Kong, G.
    Pan, X.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2017, 31 (06): : 1804 - 1815
  • [37] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [38] CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Rα1 and STAT3
    Zu, Yan
    Chen, Xiao-Fei
    Li, Qiang
    Zhang, Shu-Ting
    BIOCHEMICAL GENETICS, 2021, 59 (02) : 531 - 546
  • [39] The safety of JAK kinase inhibitors for the treatment of myelofibrosis
    Coltro, Giacomo
    Vannucchi, Alessandro M.
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (02) : 139 - 154
  • [40] Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor
    Barbour, April Marie
    Chen, Xuejun
    Yeleswaram, Swamy
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
12345